Medical & affiliate disclosure: CTX Stat provides educational laboratory information and is not a substitute for professional medical advice, diagnosis, or treatment. CTX Stat may receive compensation from some outbound provider links when an affiliate program is active; provider comparisons and rankings are based on consumer fit, effective cost, access, policies, and reputation—not commission.
Quick take
- Chromosomal microarray, often shortened to CMA, is a genetic test that looks for missing or extra pieces of chromosome material across the genome.
- It is commonly used when a clinician is evaluating unexplained developmental delay, intellectual disability, autism spectrum disorder, multiple congenital differences, certain prenatal ultrasound findings, stillbirth, products of conception, or selected cancer-related questions.
- CMA has higher resolution than a traditional karyotype for many deletions and duplications, but it does not find every genetic condition.
- Possible result categories include pathogenic, likely pathogenic, variant of uncertain significance, likely benign, benign, or no reportable finding.
- Before ordering, ask about the exact test type, sample needed, turnaround time, insurance authorization, total out-of-pocket cost, whether parental testing may be needed, and whether genetic counseling is available.
Bottom line: Chromosomal microarray is a powerful first-line genetic test in several clinical situations, especially when the question is whether a person or fetus has a clinically meaningful deletion or duplication. It is best ordered with a clear clinical reason and a plan for explaining uncertain or unexpected findings.
What is chromosomal microarray?
A chromosomal microarray is a laboratory test that examines DNA for copy number changes: segments of chromosomes that are deleted, duplicated, or sometimes present in more than two copies. These changes are called copy number variants, or CNVs. Some CNVs are harmless inherited differences. Others disrupt genes, change gene dosage, or involve chromosome regions known to cause medical or developmental conditions.
Unlike a single-gene test that focuses on one gene, CMA surveys the genome broadly. The National Center for Biotechnology Information’s GeneReviews educational materials describe CMA as a molecular genetic test used to detect CNVs, including deletions and duplications that range from small chromosome segments to very large gains or losses. Common platform types include array comparative genomic hybridization, SNP microarray, and combined oligo/SNP arrays.
In practical terms, the laboratory extracts DNA from a submitted specimen, compares signal patterns across thousands to millions of genomic markers, and uses software plus expert review to identify reportable changes. The report usually describes the chromosome region, genomic coordinates, estimated size, genes involved, clinical classification, and interpretation.
Some chromosomal microarrays include single-nucleotide polymorphism, or SNP, probes. SNP-based arrays can add information beyond simple deletions and duplications. Depending on the platform and reporting policy, they may identify regions of homozygosity, possible uniparental disomy patterns, or clues that parents are biologically related. These findings can be medically relevant, but they can also be sensitive or unexpected, which is one reason counseling before testing matters.
When is chromosomal microarray considered?
CMA is not a general wellness screen. It is usually ordered when the clinical question is strong enough that a genome-wide copy number test may help explain symptoms, guide care, clarify recurrence risk, or inform pregnancy management.
For children and adults, CMA has long been used in the evaluation of unexplained developmental delay, intellectual disability, autism spectrum disorder, and multiple congenital anomalies. The joint ACMG and ClinGen technical standards for constitutional CNV interpretation note that genome-wide copy number assessment is recommended as a first-tier approach in these postnatal settings and in prenatal evaluation when fetal structural anomalies are seen on ultrasound.
In pregnancy, chromosomal microarray may be discussed when diagnostic testing is being performed through chorionic villus sampling or amniocentesis. ACOG and SMFM state in their Committee Opinion on microarrays and next-generation sequencing in obstetrics and gynecology that CMA measures DNA gains and losses across the genome and should be offered in certain prenatal diagnostic contexts, especially when a fetus has one or more major structural abnormalities on ultrasound.
CMA may also be used on products of conception or stillbirth tissue when clinicians are trying to understand whether a chromosome imbalance contributed to pregnancy loss. In oncology, microarray testing may be used for selected tumor or blood-cancer questions, but cancer microarray testing has different goals and interpretation rules than constitutional testing. If you are ordering a test for a child’s development, a pregnancy, pregnancy loss, or a tumor, make sure the order matches the clinical setting.
Chromosomal microarray vs. other genetic tests
Many people first hear about CMA after another test, such as NIPT, karyotype, FISH, Fragile X testing, exome sequencing, or a gene panel. These tests are not interchangeable. They answer different questions.
| Test | What it is best at finding | Common limitations |
|---|---|---|
| Chromosomal microarray | Genome-wide deletions and duplications; some SNP arrays also detect regions of homozygosity or possible UPD patterns | Usually misses balanced translocations/inversions, many single-gene sequence variants, repeat expansions, and low-level mosaicism |
| Karyotype | Whole-chromosome gains or losses; large structural rearrangements; balanced translocations and inversions visible under a microscope | Lower resolution for small deletions or duplications; may require cell culture |
| FISH | A targeted chromosome region or known suspected abnormality | Does not scan the genome broadly unless multiple probes are used |
| NIPT / cell-free DNA screening | Screening for selected fetal chromosome conditions using placental DNA fragments in maternal blood | Screening, not diagnostic; positive or atypical results often require diagnostic confirmation |
| Gene panel or exome sequencing | Sequence variants in many genes; may detect some exon-level deletions/duplications depending on method | May miss chromosome-level copy number changes, repeat expansions, noncoding variants, or variants outside the test scope |
A common misconception is that a chromosomal microarray is “more complete” than every other test. It is more detailed than karyotype for many copy number changes, but it is less useful for other variant types. For example, GeneReviews notes that CMA generally cannot detect balanced chromosome rearrangements and cannot always determine where duplicated material is located in the genome. That means a person can have a normal CMA and still have a genetic condition that requires a different testing method.
What happens before and during the test?
The ordering process depends on the reason for testing. In a typical postnatal evaluation, the specimen may be blood, saliva, or a cheek swab. Blood is often preferred because it usually provides high-quality DNA and may reduce some sample problems. For prenatal diagnosis, DNA may come from chorionic villus sampling or amniocentesis. For pregnancy-loss testing, tissue handling is especially important because maternal cell contamination can complicate interpretation.
Before the specimen is collected, you should know what type of CMA is being ordered, why it is being ordered, and what kinds of results may be returned. Pretest counseling does not need to be frightening or overly technical, but it should cover realistic benefits and limitations. Important topics include the possibility of uncertain results, findings unrelated to the original question, parental testing, incidental information about biological relationships, and the fact that a normal result does not rule out all genetic causes.
There is usually no fasting or medication restriction for a blood, saliva, or cheek-swab CMA. However, follow the laboratory’s collection instructions closely. Saliva kits may require avoiding food, drink, gum, or brushing teeth for a period before collection. Blood transfusion, bone marrow transplant, or active blood cancer history may affect which sample type is appropriate, so those details should be shared with the ordering clinician and laboratory.
How chromosomal microarray results are interpreted
CMA interpretation is not just a size measurement. A small deletion that disrupts a critical gene can be important, while a larger duplication in a benign region may not explain a person’s symptoms. Laboratories evaluate many factors, including the chromosome region, gene content, inheritance, known disease associations, published cases, population frequency, databases, and whether the finding fits the patient’s features.
The ACMG/ClinGen standards use an evidence-based framework for classifying constitutional copy number variants. Reports commonly use categories such as:
- Pathogenic: Strong evidence supports that the CNV causes or contributes to disease.
- Likely pathogenic: Evidence strongly suggests clinical relevance, but may not be as definitive as pathogenic.
- Variant of uncertain significance: The lab cannot yet determine whether the CNV is disease-causing or benign.
- Likely benign or benign: Evidence suggests the CNV is not clinically meaningful.
- No reportable finding: The test did not identify a result that meets the lab’s reporting criteria.
A pathogenic or likely pathogenic result may provide a diagnosis, explain part of a person’s medical or developmental history, change surveillance recommendations, or prompt referrals. It may also help family members understand recurrence risk. Sometimes, parental testing is recommended to see whether the CNV was inherited or occurred de novo, meaning it was not detected in either parent. Inheritance can matter, but it does not always settle the clinical significance. Some inherited CNVs have variable expression, meaning one person may have significant features while another relative has mild or no obvious symptoms.
A variant of uncertain significance, often called a VUS, can be frustrating. It is not a diagnosis by itself, and it should not be treated as proof that a condition is or is not present. A genetics professional may review whether the finding overlaps known genes, whether either parent carries it, and whether reclassification is possible in the future. If the person’s medical picture changes, or if new research emerges, the interpretation may change.
What chromosomal microarray can miss
The most important thing to understand before ordering CMA is that “normal” does not mean “nothing genetic is going on.” It means the laboratory did not find a reportable abnormality within the test’s detection limits and reporting criteria.
| CMA may detect | CMA usually does not detect well |
|---|---|
| Deletions and duplications above the lab’s reporting threshold | Single-letter DNA sequence variants in most genes |
| Some whole-chromosome aneuploidies | Balanced translocations and inversions |
| Some mosaic copy number changes, if present at a detectable level | Low-level mosaicism below the lab’s limit of detection |
| Regions of homozygosity on SNP-based platforms | Many repeat expansion disorders, such as Fragile X, unless separately tested |
| Possible uniparental disomy patterns on some SNP arrays | Epigenetic or methylation abnormalities unless a specific test is ordered |
Another limitation is phenotype fit. A CMA report may list genes and syndromes, but the result still needs to be interpreted in the context of the patient or pregnancy. Two people with the same CNV can have different symptoms. Conversely, a person’s symptoms may be caused by a genetic mechanism that CMA cannot detect.
Technical factors also matter. The exact probe density, reporting thresholds, genome build, SNP coverage, specimen type, and laboratory policy can affect what is found and reported. The 2021 ACMG technical standard for chromosomal microarray analysis discusses laboratory design, validation, specimen considerations, and performance expectations for constitutional and neoplastic applications, underscoring that CMA is a laboratory-developed process requiring validated methods and expert interpretation.
Cost, insurance, and total out-of-pocket questions
Chromosomal microarray costs vary widely in the United States. The amount a consumer pays may depend less on the “list price” and more on insurance coverage, deductible status, network contracts, prior authorization, specimen collection fees, and whether follow-up testing is needed. In prenatal testing, the cost discussion should also separate the genetic test from the procedure used to obtain the specimen, such as amniocentesis or chorionic villus sampling.
When comparing options, focus on the effective total cost, not just the lab test price. A low advertised cash price may not include the clinician visit, genetic counseling, blood draw, shipping, repeat sample collection, parental studies, or confirmatory testing. A hospital-based test may have facility billing that differs from a reference laboratory order. Some laboratories provide patient-pay programs, financial assistance, or pre-test benefit investigations; others require the ordering clinician or patient to request a good-faith estimate.
Major laboratories often route pricing through estimate tools or billing offices rather than posting one universal national cash price. For example, Quest Diagnostics states that self-pay pricing can be requested through its self-pay price estimate process, while Mayo Clinic Laboratories notes that test fees depend on multiple factors and directs clients to its test price lookup or customer service process. Because pricing and network status can change, verify the estimate for the exact test code and ordering route before the sample is collected.
Questions to ask before ordering:
- What is the exact test name and test code?
- Is this a constitutional, prenatal, products-of-conception, or tumor microarray?
- Which laboratory will perform the test, and is it in network for my plan?
- Is prior authorization required?
- What CPT codes will be billed?
- What is the estimated total cost if insurance denies coverage?
- Are collection, shipping, counseling, procedure, or parental testing fees separate?
- What kinds of uncertain or incidental findings can be reported?
- Who will explain the result and coordinate follow-up?
What to do after results come back
If the result is abnormal or uncertain, schedule a discussion with the ordering clinician, genetic counselor, medical geneticist, maternal-fetal medicine specialist, or other qualified professional. Ask for a plain-language explanation of what was found, how confident the classification is, whether the finding fits the clinical picture, and whether parental testing, confirmatory testing, imaging, specialty care, or developmental services are recommended.
If the result is normal, ask what the next step is based on the original reason for testing. For developmental delay or congenital differences, next steps might include Fragile X testing, exome or genome sequencing, targeted gene testing, metabolic evaluation, hearing or vision evaluation, neurology, developmental pediatrics, or therapy referrals. In pregnancy, next steps may include ultrasound follow-up, fetal echocardiography, targeted testing, or no further genetic testing, depending on the findings and goals of care.
Keep a copy of the full laboratory report, not just the patient portal summary. Genetic interpretations can evolve. If a VUS is reported, ask whether the laboratory has a reclassification process and whether your clinician’s office will be notified if the classification changes.
Frequently asked questions
Is chromosomal microarray painful?
The microarray itself is performed on DNA in a laboratory. For postnatal testing, the sample collection may be a routine blood draw, saliva sample, or cheek swab. In pregnancy, the DNA sample may come from amniocentesis or chorionic villus sampling, which are medical procedures with their own risks and counseling needs.
How long does chromosomal microarray take?
Turnaround time varies by laboratory and specimen type. Many postnatal blood or saliva CMAs take about one to four weeks after the laboratory receives an acceptable specimen, but prenatal, tissue, tumor, or complex cases may take longer. Ask the ordering clinician which timeline applies to your exact test.
Can chromosomal microarray diagnose autism?
CMA does not diagnose autism by itself. Autism spectrum disorder is diagnosed clinically based on developmental and behavioral criteria. CMA can sometimes identify a genetic copy number change associated with autism or related developmental differences, which may help explain the cause or guide medical care.
Can CMA find Down syndrome?
Many chromosomal microarrays can detect an extra chromosome 21 or a large duplication involving chromosome 21. However, the best test depends on the clinical context. Karyotype may still be useful when clinicians need to understand the structure of the chromosomes, such as whether a translocation is present.
What is a VUS on chromosomal microarray?
A VUS is a variant of uncertain significance. It means the lab found a copy number change, but current evidence is not enough to classify it as disease-causing or benign. A VUS should be interpreted with the patient’s medical features, family history, inheritance testing when appropriate, and updated evidence over time.
Should parents be tested too?
Sometimes. If a child or fetus has a CNV, parental testing may help determine whether it was inherited or de novo. That information can affect recurrence-risk counseling and interpretation, but it does not always provide a simple answer because some CNVs have variable effects.
Is CMA better than exome sequencing?
Neither test is universally better. CMA is designed to detect copy number changes across the genome. Exome sequencing is designed to detect many sequence variants in protein-coding genes and may or may not reliably detect all CNVs. Clinicians often choose based on the person’s features, prior test results, and the most likely genetic mechanism.
Can I order chromosomal microarray on my own?
In most clinical situations, CMA is ordered by a healthcare professional because test selection, consent, specimen requirements, insurance authorization, and result interpretation can be complex. Some consumer-facing genetic testing companies offer broad DNA testing, but those products are not the same as a clinically ordered chromosomal microarray with medical interpretation.
Sources
- GeneReviews: Genetic Testing — Current Approaches
- ACMG/ClinGen: Technical standards for interpretation and reporting of constitutional copy number variants
- ACMG: Chromosomal microarray analysis technical standard, 2021 revision
- ACOG/SMFM: Microarrays and next-generation sequencing technology in obstetrics and gynecology
- Quest Diagnostics: Self-pay price estimate process
- Mayo Clinic Laboratories: Test prices and estimate process
